Malaysia mRNA Vaccines and RNAi Therapeutics Market (2025-2031) | Outlook, Competitive Landscape, Analysis, Trends, Forecast, Growth, Industry, Share, Segmentation, Value, Companies, Size & Revenue

2.1 Key Highlights of the Report

2.2 Report Description

2.3 Market Scope & Segmentation

2.4 Research Methodology

2.5 Assumptions

3.1 Malaysia Country Macro Economic Indicators

3.2 Malaysia mRNA Vaccines and RNAi Therapeutics Market Revenues & Volume, 2021 & 2031F

3.3 Malaysia mRNA Vaccines and RNAi Therapeutics Market - Industry Life Cycle

3.4 Malaysia mRNA Vaccines and RNAi Therapeutics Market - Porter's Five Forces

3.5 Malaysia mRNA Vaccines and RNAi Therapeutics Market Revenues & Volume Share, By Disease Type, 2021 & 2031F

3.6 Malaysia mRNA Vaccines and RNAi Therapeutics Market Revenues & Volume Share, By Administration, 2021 & 2031F

3.7 Malaysia mRNA Vaccines and RNAi Therapeutics Market Revenues & Volume Share, By End user, 2021 & 2031F

4.1 Impact Analysis

4.2 Market Drivers

4.2.1 Increasing prevalence of chronic diseases in Malaysia

4.2.2 Growing investments in healthcare infrastructure and research and development

4.2.3 Government support and initiatives to promote innovative therapies

4.3 Market Restraints

4.3.1 High cost of mRNA vaccines and RNAi therapeutics

4.3.2 Limited awareness and acceptance of mRNA vaccines and RNAi therapeutics among healthcare professionals and patients

4.3.3 Regulatory challenges and approval processes for new therapies

6.1 Malaysia mRNA Vaccines and RNAi Therapeutics Market, By Disease Type

6.1.1 Overview and Analysis

6.1.2 Malaysia mRNA Vaccines and RNAi Therapeutics Market Revenues & Volume, By Disease Type, 2021- 2031F

6.1.3 Malaysia mRNA Vaccines and RNAi Therapeutics Market Revenues & Volume, By Hereditary transthyretin-mediated amyloidosis genetic, 2021- 2031F

6.1.4 Malaysia mRNA Vaccines and RNAi Therapeutics Market Revenues & Volume, By Acute hepatic porphyria, 2021- 2031F

6.1.5 Malaysia mRNA Vaccines and RNAi Therapeutics Market Revenues & Volume, By Primary hyperoxaluria type 1, 2021- 2031F

6.1.6 Malaysia mRNA Vaccines and RNAi Therapeutics Market Revenues & Volume, By Atherosclerotic cardiovascular disease, 2021- 2031F

6.2 Malaysia mRNA Vaccines and RNAi Therapeutics Market, By Administration

6.2.1 Overview and Analysis

6.2.2 Malaysia mRNA Vaccines and RNAi Therapeutics Market Revenues & Volume, By IV infusion, 2021- 2031F

6.2.3 Malaysia mRNA Vaccines and RNAi Therapeutics Market Revenues & Volume, By Subcutaneous, 2021- 2031F

6.3 Malaysia mRNA Vaccines and RNAi Therapeutics Market, By End user

6.3.1 Overview and Analysis

6.3.2 Malaysia mRNA Vaccines and RNAi Therapeutics Market Revenues & Volume, By Research Institutes, 2021- 2031F

6.3.3 Malaysia mRNA Vaccines and RNAi Therapeutics Market Revenues & Volume, By Hospitals and Clinics, 2021- 2031F

7.1 Malaysia mRNA Vaccines and RNAi Therapeutics Market Export to Major Countries

7.2 Malaysia mRNA Vaccines and RNAi Therapeutics Market Imports from Major Countries

8.1 Number of clinical trials for mRNA vaccines and RNAi therapeutics in Malaysia

8.2 Research and development expenditure in the biopharmaceutical sector

8.3 Number of partnerships and collaborations between local and international pharmaceutical companies in the mRNA vaccines and RNAi therapeutics space

9.1 Malaysia mRNA Vaccines and RNAi Therapeutics Market Opportunity Assessment, By Disease Type, 2021 & 2031F

9.2 Malaysia mRNA Vaccines and RNAi Therapeutics Market Opportunity Assessment, By Administration, 2021 & 2031F

9.3 Malaysia mRNA Vaccines and RNAi Therapeutics Market Opportunity Assessment, By End user, 2021 & 2031F

10.1 Malaysia mRNA Vaccines and RNAi Therapeutics Market Revenue Share, By Companies, 2024

10.2 Malaysia mRNA Vaccines and RNAi Therapeutics Market Competitive Benchmarking, By Operating and Technical Parameters